iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 1857

Identifiers

  • Canonical SMILES: 
    Cc1[nH]c(c2CCCC(=O)c12)-c1cc(NS(C)(=O)=O)ccc1Oc1ccccc1
  • IUPAC name: 
    N-[3-(3-methyl-4-oxo-4,5,6,7-tetrahydro-2H-isoindol-1-yl)-4-phenoxyphenyl]methanesulfonamide
  • InChi: 
    InChI=1S/C22H22N2O4S/c1-14-21-17(9-6-10-19(21)25)22(23-14)18-13-15(24-29(2,26)27)11-12-20(18)28-16-7-4-3-5-8-16/h3-5,7-8,11-13,23-24H,6,9-10H2,1-2H3
  • InChiKey: 
    GZFJPALDEYOFHA-UHFFFAOYSA-N

External links


71760902
CHEMBL4063051
87P

External search

Bibliography (1)

Publication Name
Hasvold Lisa A., Sheppard George S., Wang Le, Fidanze Steven D., Liu Dachun, Pratt John K., Mantei Robert A., Wada Carol K., Hubbard Robbert, Shen Yu, Lin Xiaoyu, Huang Xiaoli, Warder Scott E., Wilcox Denise, Li Leiming, Buchanan F. Greg, Smithee Lauren, Albert Daniel H., Magoc Terrance J., Park Chang H., Petros Andrew M., Panchal Sanjay C., Sun Chaohong, Kovar Peter, Soni Nirupama B., Elmore Steven W., Kati Warren M., McDaniel Keith F.. . Methylpyrrole inhibitors of BET bromodomains Bioorganic & Medicinal Chemistry Letters. 15

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 2 2 0

Targets

PPI family Best activity Diseases MMoA
Bromodomain / Histone 7.48 cancer Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 410.13 g/mol
HBA 6
HBD 2
HBA + HBD 8
AlogP 3.00
TPSA 88.26
RB 4
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 1 2 2 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
10.1016/j.bmcl.2017.02.057 15 BRD4
O60885 		H4
P62805 		Biochemical assay Time-Resolved FRET pKi (inhibition constant, -log10) 7.48
10.1016/j.bmcl.2017.02.057 15 BRD4
O60885 		H4
P62805 		Cellular assay MX-1 proliferation assay MX-1 pEC50 (half maximal effective concentration, -log10) 6.80
10.1016/j.bmcl.2017.02.057 15 BRD4
O60885 		H4
P62805 		Cellular assay Luciferase reporter H1299 pEC50 (half maximal effective concentration, -log10) 7.29
PK data
Bibliography Name Assay name Administration mode Dose (mg/kg) Dose interval (hours) Tolerated AUC Clearance Cmax Oral bioavailability T1/2 (min) Tmax (min) Volume distribution (Vd)
10.1016/j.bmcl.2017.02.057 15 Mouse PK IV IV 3.00 None yes no yes no 30 36 None no
10.1016/j.bmcl.2017.02.057 15 Mouse PK PO PO 10.00 None yes yes no no 30 None None no
Ta Structure Name Drugbank ID
0.5000 N-[(13-CYCLOHEXYL-6,7-DIHYDROINDOLO[1,2-D][1,4]BENZOXAZEPIN-10-YL)CARBONYL]-2-METHYL-L-ALANINE DB08031
0.4335 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE DB07364
0.4136 AKI-001 DB07266
0.4103 3-CYCLOHEXYL-1-(2-MORPHOLIN-4-YL-2-OXOETHYL)-2-PHENYL-1H-INDOLE-6-CARBOXYLIC ACID DB07570
0.4084 Molindone DB01618
0.4052 Beclabuvir DB12225
0.4000 2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DB08358
0.3992 Atorvastatin DB01076
0.3985 Mirodenafil DB11792
0.3976 Pyrroloquinoline Quinone DB03205
0.3943 Birinapant DB11782
0.3917 CRA_17312 DB02084
0.3876 N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE DB07991
0.3864 Dasabuvir DB09183
0.3843 Saroglitazar DB13115